Screener
Ligand Pharmaceuticals LGND Unrealized Losses on Investments (Before Tax)
Unrealized Losses on Investments (Before Tax) at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| June 30, 2026 | Amortized cost | Gross unrealized gains | Gross unrealized losses | Estimated fair value |
|---|---|---|---|---|
| Corporate notes/bonds | 52,307 | — | (130) | 52,177 |
| Corporate equity securities | 20,850 | 63,477 | (3,314) | 81,013 |
| Commercial paper | 7,430 | — | (6) | 7,424 |
| Total short-term investments | $291,586 | $63,477 | $(4,007) | $351,056 |
| December 31, 2025 | ||||
| U.S. Government Agencies | $175,780 | $89 | $(38) | $175,831 |
| Corporate notes/bonds | 124,249 | 98 | (52) | 124,295 |
| U.S. Treasuries | 113,055 | 137 | (4) | 113,188 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's unrealized losses on investments (before tax)?
- Ligand Pharmaceuticals (LGND) reported unrealized losses on investments (before tax) of $4.01M in Q2 2026.
- How has Ligand Pharmaceuticals's unrealized losses on investments (before tax) changed year-over-year?
- Ligand Pharmaceuticals's unrealized losses on investments (before tax) increased by 103.2% year-over-year, from $1.97M to $4.01M.
- What is the long-term trend for Ligand Pharmaceuticals's unrealized losses on investments (before tax)?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's unrealized losses on investments (before tax) has grown at a 22.9% compound annual growth rate (CAGR), from $1.39M to $3.89M.
- What does unrealized losses on investments (before tax) mean?
- The total unrealized losses on investments, typically related to available-for-sale securities, before considering tax effects.
Ask your AI about Ligand Pharmaceuticals's unrealized losses on investments (before tax).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude